StocksMedium•28 September 2026•
1 min read
FDA Approves AbbVie's JUVMO for Parkinson's Disease Treatment
Key Facts
1The U.S. FDA approved JUVMO (tavapadon) as the first and only selective D1/D5 receptor agonist for treating adults with Parkinson's disease.
The U.S. FDA approved JUVMO (tavapadon) as the first and only selective D1/D5 receptor agonist for treating adults with Parkinson's disease. AbbVie said in a statement reported by PR Newswire that the treatment is a once-daily oral medication supported by data from the Phase 3 TEMPO clinical trial program.
Clinical trials demonstrated significant improvements in daily functioning and increased "on" time without troublesome dyskinesia for patients. Regarding market performance, ABBV closed at $264.34 on September 25, 2026, with the stock trading between a low of $262.59 and a high of $266 during that session.